Limertinib is a potent tyrosine kinase inhibitor designed to treat systemic mastocytosis and other hematologic malignancies by selectively inhibiting KIT and PDGFR beta receptors. By blocking signaling… Read more
Limertinib is a potent tyrosine kinase inhibitor designed to treat systemic mastocytosis and other hematologic malignancies by selectively inhibiting KIT and PDGFR beta receptors. By blocking signaling pathways responsible for abnormal cell proliferation, this compound plays a vital role in targeted therapeutic strategies. To support robust analytical testing and quality control within pharmaceutical laboratories, this category provides high-quality reference standards essential for comprehensive impurity profiling. These include Limertinib Impurity 1, a critical degradation product required for monitoring stability and synthesis integrity. Additionally, the collection features stable isotope labelled compounds, such as Limertinib-13C-d3, which serve as precise internal standards for mass spectrometry-based assays. Researchers rely on these analytical tools to validate method accuracy, ensure regulatory compliance, and quantify impurities during method development and routine batch release testing of this specialized oncological treatment.